Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
This week in R&D: ULA launches second rocket, Microsoft sets up AI in Italy, and India and ...
R&D World Index (RDWI) closed at 4,005.40, up 0.62%. Eight members gained, led by Alibaba (+6.71%), while 17 lost value, with Stellantis NV (-17.06%). Highlights include ULA's second Vulcan Centaur rocket launch, Microsoft's $4.75B investment in Italy's cloud and AI, Eli Lilly's $4.5B drug center, and India-US R&D collaboration talks.
Global Dermatology Drugs Market to Worth Over US$ 50.42
The global dermatology drugs market is projected to reach $50.42 billion by 2032 from $19.71 billion in 2023, driven by innovations in AI, genomics, and personalized medicine. Key players like Novartis, Pfizer, and Johnson & Johnson lead with advanced treatments, while Europe's high prevalence of skin conditions and robust healthcare infrastructure support market growth.
Look Who's Talking at HLTH
HLTH 2024, Oct 20-23 in Las Vegas, features speakers like Meta's Fred Abnousi, Pfizer's Karin Tollefson, Kaiser Permanente's Greg Adams, and actress Halle Berry discussing healthcare innovations, AI in medicine, and patient experiences, among other topics.
The future of multiple myeloma is personalised, but we must work together to deliver it
Myeloma remains incurable, with treatment resistance increasing with each relapse. Personalised therapies are crucial due to myeloma's heterogeneity. Clinical trials must diversify to represent all patient populations, addressing ethnic disparities. Real-world evidence is essential for personalised care, requiring standardised collection and assessment methods. Patient needs should drive R&D, ensuring treatments are practical and effective.
Johnson & Johnson submits new Monarch surgical robot software for FDA clearance
Johnson & Johnson MedTech filed an FDA 510(k) submission for the latest Monarch platform software release, designed for bronchoscopic visualization and access to adult patient airways, enabling minimally invasive, robotic-assisted technology for peripheral lung procedures.
J&J seeks new FDA approval of Darzalex Faspro myeloma combo
Johnson & Johnson seeks FDA approval for Darzalex Faspro-based quadruple regimen for newly diagnosed multiple myeloma patients not initially planning stem cell transplant. The D-VRd combo, already approved for transplant-eligible patients, showed significant benefits in the CEPHEUS trial, including higher MRD-negativity rates and reduced disease progression risk.
Related Clinical Trials:
Distinct Alzheimer Disease Subtypes Using Proteomic Fingerprints: Fiona Elwood, PhD
Alzheimer's disease subtypes identified through CSF proteomics data: (1) neuronal plasticity, (2) innate immunity, (3) blood-brain barrier dysfunction. These subtypes highlight the need for precision medicine in AD treatment.
Phase 3 Study of TAR-200/Cetrelimab Is Discontinued in MIBC
Johnson & Johnson halts phase 3 SunRISe-2 trial evaluating TAR-200 and cetrelimab vs chemoradiation for muscle-invasive bladder cancer (MIBC) patients not undergoing radical cystectomy, following an interim analysis. The company remains confident in TAR-200's potential, with ongoing studies and an FDA filing planned for early 2025.
Related Clinical Trials:
Johnson & Johnson discontinues Phase III study of treatment for bladder cancer
Johnson & Johnson discontinued SunRISe-2 study for TAR-200 in MIBC patients not undergoing radical cystectomy after interim analysis showed no superiority to chemoradiation. However, potential for TAR-200 is seen in SunRISe-4 study, with plans for FDA filing of TAR-200 monotherapy based on SunRISe-1 trial data.
© Copyright 2024. All Rights Reserved by MedPath